aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Shoreline Biosciences, founded with a mission to revolutionize cancer treatment, focuses on developing next-generation immunotherapies. The company leverages its proprietary cell therapy technology platform, which includes expertise in induced pluripotent stem cell (iPSC) differentiation and genetic programming of the IL-15/CISH pathway. This approach enhances the metabolic fitness and persistence of engineered natural killer (NK) cells, aiming to improve their anti-cancer activity. Shoreline's core products include iPSC-derived NK cells (iNK) and macrophage cell therapies (iMACs), targeting the oncology market.
Notable figures affiliated with Shoreline Biosciences include leading scientists and industry experts in cellular immunotherapy. The company has attracted significant investment from prominent venture capital firms, underscoring its potential impact in the biotech sector. Key achievements include the development of a robust pipeline of iNK and iMAC candidates and advancing preclinical studies demonstrating enhanced anti-cancer efficacy. Shoreline's innovative approach has positioned it as a promising player in the fight against cancer, pushing the boundaries of scientific possibilities to deliver novel therapies to patients in need.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Cell Therapy, Immunotherapy
Technology
Biotech
Tags
Healthtech
Model Types
Platform, Software
Revenue Type(s)
Consulting
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Shoreline Biosciences founded?
Shoreline Biosciences was founded in 2020.
Where is Shoreline Biosciences's headquarters located?
Shoreline Biosciences's headquarters is located in Los Angeles, CA, US.
When was Shoreline Biosciences's last funding round?
Shoreline Biosciences's most recent funding round was for $140M (USD) in November 2021.
How many employees does Shoreline Biosciences have?
Shoreline Biosciences has 101 employees as of Feb 5, 2024.
How much has Shoreline Biosciences raised to-date?
As of July 05, 2023, Shoreline Biosciences has raised a total of $186M (USD) since Nov 2, 2021.
Add Comparison
Total Raised to Date
$186M
USD
Last Update Nov 2, 2021
Last Deal Details
$140M
USD
Nov 2, 2021
Series B
Total Employees Over Time
101
As of Feb 2024
Shoreline Biosciences Address
7452 Herschel Avenue
Los Angeles,
California
92037
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts